Skip to main content

Table 1 Baseline characteristics of patients and controls

From: Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis

 

Patients with RA (n = 31)

Control group (n = 17)

p

Women

58.1% (n = 18)

41.2% (n = 7)

0.367

Age

57 (48–61)a

41 (29–68)a

0.131

BMI (kg/m2)

25.8 (22.2–33)a

24.0 (22.16–26.30)a

0.343

Medical history of smoking

48.4% (n = 15)

23.5% (n = 4)

0.127

Consumption (packets per year)

20 (11–28)a

0 (0–5)a

0.094

Recent RA ≤2 years

32.3% (n = 10)

-

 

Antibodies

 RF+

74.2% (n = 23)

-

 

 ACPA+

80.6% (n = 25)

-

 

Structural damage (erosions)

41.9% (n = 13)

-

 

NSAID

12.9% (n = 4)

-

 

Corticoids

54.8% (n = 17)

-

 

Median dosage (mg/day)

5 (5–6)a

-

 

Methotrexate

64.5% (n = 20)

-

 

Median dose (mg/week)

15 (10–20)a

-

 

Initiation (1st line of biomedicine)

54.8% (n = 17)

-

 

Abatacept

38.7% (n = 12)

-

 

Tocilizumab

19.4% (n = 6)

-

 

Anti-TNF drugs

Golimumab

16.1% (n = 5)

-

 

Etanercept

22.6% (n = 7)

-

 

Certolizumab

3.2% (n = 1)

-

 

ESR (mm)

14 (6–31)a

-

 

CRP (mg/L)

7.9 (3.0–23.2)a

-

 

DAS28

4.24 (3.70–5.32)a

-

 

DAS28-CRP

4.42 (3.69–5.11)a

-

 

HAQ

1.63 (1–2)a

-

 
  1. aResults expressed as median and 25th and 75th percentiles. The Mann–Whitney test was used for quantitative variables; the Fisher exact test was used for other variables (male/female, tobacco precursor). RA rheumatoid arthritis, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, HAQ Health Assessment Questionnaire, NSAID nonsteroidal anti-inflammatory drugs